Myocardial salvaging effects of berberine in experimental diabetes co-existing with myocardial infarction

Journal of Clinical and Diagnostic Research

Volumn 10, Issue 3, 2016, Pages FF13-FF18

  Suman, Rajesh Kumar ^a   Borde, Manjusha K ^a   Mohanty, Ipseeta Ray ^a   Maheshwari, Ujwala ^a   Deshmukh, Y A ^a  

^a MGM Medical College   (India)

Author keywords

Berberis aristata; Cardioprotective effects; DPP IV inhibitor; Isoproterenol

Indexed keywords

BERBERINE; CREATINE KINASE MB; HEMOGLOBIN A1C; ISOPRENALINE; STREPTOZOCIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ANTILIPEMIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG ACTIVITY; EXPERIMENTAL DIABETES MELLITUS; HEART; HEART INFARCTION; HEART MUSCLE; HEART PROTECTION; HISTOPATHOLOGY; KIDNEY; KIDNEY FUNCTION; LIVER; LIVER FUNCTION; MALE; NONHUMAN; PANCREAS; RAT;

EID: 84960076363     PISSN: 2249782X     EISSN: 0973709X     Source Type: Journal    
DOI: 10.7860/JCDR/2016/15794.7459     Document Type: Article

References (28)

1. Barragan JM, Rodriguez RE, Blazquez E. Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats. Am J Physiol. 1994;266:E459–66.
2. Gros R, You X, Baggio L. Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology. 2003;144:2242–52.
3. Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 2004;109:962–65.
4. Ramis JN, Comas LM. The new antidiabetic agents in the firing line… safety reasons or witch hunt? Endocrinol Nutr. 2012;59(1):1-8.
5. Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials. Diabetes, Obesity and Metabolism. 2014;16:48-56.
6. Elashoffo M, Aleksey V, Gier MB, Elashoff R, PC Butler. Pancreatits, pancreatic and Thyroid cancer with glucagon-link peptide-1-based therapies. Gastroenterology. 2011;141:150-56.
7. Zhao X, Zhang J, Tong N, et al. Berberine attenuates doxorubicin-induced cardiotoxicity in mice. The Journal of International Medical Research. 2011;39(5):1720-27.
8. Feng Y, Siu KY, Ye X, Wang N, Yuen MF, Leung CH, et al. Hepatoprotective effects of berberine on carbon tetrachloride-induced acute hepatotoxicity in rats. Chinese Medicine. 2010;5:33.
9. Al-masri IM, Mohammad MK, Tahaa MO. Inhibition of dipeptidyl peptidase IV (DPP IV) is one of the mechanisms explaining the hypoglycaemic eect of berberine. Journal of Enzyme Inhibition and Medicinal Chemistry. 2009;24(5):1061–66.
10. Affuso F, Mercurio V, Fazio V. Cardiovascular and metabolic effects of Berberine. World Journal of Cardiology. 2010;2(4):71-77.
11. Agrawal YO, Sharma PK, Shrivastava B, Arya DS, Goyal SN. Hesperidin blunts streptozotocin-isoproternol induced myocardial toxicity in rats by altering of PPAR-γ receptor. Chem Biol Interact. 2014;219:211-20.
12. Lu SS, Yu YL, Zhu HJ, Liu XD, Liu I, Liu YW, et al. Berberine promotes glucagon-link peptide-1(7-36) amide secretion in Streptozotocin-induced diabetic rats. J endocrinol. 2009;200:159-65.
13. Kim SH, Shin EJ, Kim ED, et al. Berberine activates GLUTI-mediated glucose uptake in 3T3-L1 adipocytes. Biol Pharm bull. 2007;30:1431-37.
14. Leng SH, Lu FE, Xu IJ. Therapeutic effects of berberine in impaired glucose tolerance rats and its influence on insulin secretion. Acta Pharmacol Sin. 2004;25:496-502.
15. Zhang H, Wei J, Xue R, Wu JD, Zhao W, Wang ZZ, et al. Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism. 2010;59(2):285-92.
16. Adams JE, Abendschein DR, Jaffe AS. Biochemical markers of myocardial injury. Is MB creatinekinase the choice for 1990s? Circulation.1994;88:750–63.
17. Zhang T, Yang S, Du J. Protective Effects of Berberineon Isoproterenol-induced Acute Myocardial Ischemiain Rats through Regulating HMGB1-TLR4Axis. Evidence-Based Complementary and Alternative Medicine. 2014;1-8.
18. Punitha ISR, et al. Antidiabetic activity of benzyl tetra isoquinoline alkaloid of berberine in Streptozotocin –nicotinamide induced type 2 diabeic rats. Diabetologia Croatica. 2006;34(4):117-28.
19. Padmanabhan M, Prince P SM. Effects of pharmacological amounts of S-allylcysteine on lipids in normal and isoproterenol-induced myocardial infarction in rats. Journal of the Science of Food and Agriculture. 2006;86:772–77.
20. Maulik MG, Seth SD, Manchanda SC, Singh U, Maulik SK. Isoproterenol fails to produce myocardial necrosis in streptozotocin-induced diabetic rats. Indian J Exp Biol. 1991;29(9):837-40.
21. Gotzsche O. Lack of cardiotoxic effect of isoproterenol in streptozotocin diabetic rats.Amorphometric study of isoproterenol induced fibrosis. Virchows Arch A Pathol Anat Histol. 1982;397(1):83-91.
22. Sellers DJ, Chess-Williams R. The effect of streptozotocin-induced diabetes on cardiac beta-adrenoceptor subtypes in the rat. J Auton Pharmacol. 2001;21(1):15-21.
23. Slater AM, White DA. Effect of dietary fat on cholesterol metabolism: regulation of plasma LDL concentrations. Nutr Res.1996;9:241–57.
24. Gerich JE. Contributions of insulin-resistance and insulin-secretory defects to the pathogenesis of type 2 diabetes mellitus. Mayo Clinic Proceedings. 2003;78(4):447–56.
25. Nakano K, Hasegawa G, Fukuietal M. Effect of pioglitazone on various parameters of insulin resistance including lipoprotein subclass according to particle size by agel-permeation high-performance liquid chromatography in newly diagnosed patients with type 2 diabetes. Endocrine Journal. 2010;57(5):423–30.
26. Delarue J, Magnan C. Free fatty acids and insulin resistance. Current Opinionin Clinical Nutrition and Metabolic Care. 2007;10(2):142–48.
27. Chen Y, Wang Y, Zhang J, Sun C, Lopez A. Berberine Improves Glucose Homeostasis in Streptozotocin-Induced Diabetic Rats in Association with Multiple Factors of Insulin Resistance. Endocrinol. 2011;2011:8.
28. Heidarian E, Rafieian-Kopaei M, Khoshdel A, Bakhshesh M. Metabolic effects of berberine on liver phosphatidate phosphohydrolase in rats fed on high lipogenic diet: an additional mechanism for the hypolipidemic effects of berberine. Asian Pacific Journal of Tropical Biomedicine. 2014;4(1):S429-35.